Room 4331, 3th building, high-tech industrial park, yizhi road, qingshan district, wuhan, China
Home ProductsOral Anabolic steroids

Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7

Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7

  • Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7
  • Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7
  • Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7
  • Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7
  • Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7
Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7
Product Details:
Place of Origin: Hubei, China
Brand Name: Dostinex
Certification: ISO9001, SGS
Model Number: CAS 81409-90-7
Payment & Shipping Terms:
Minimum Order Quantity: 1bottle, 25pills
Price: USD50/kit
Packaging Details: Plastic Bottle
Delivery Time: 3-7 days
Payment Terms: Western Union, MoneyGram, , T/T, wechat, Alipay
Supply Ability: 200 bottles per month
Contact Now
Detailed Product Description
Product Name: Dostinex Specification: 0.5mg*25pcs Per Bottle
Other Name: Cabergoline Shipping Method: Fedex, DHL, TNT, UPS, EMS, HK EMS, EUB...
Export Market: USA, UK, Thailand, Brazil, France, Spain... MOQ: 1 Bottle, 25pcs
Function: Male Enhancement, Weight Loss, Big Muscle Type: Adhesive Sticker, Anabolic Steroids
Purity: >99% Whatsapp: +8613429837396
High Light:

legal anabolic steroids

,

bodybuilding oral steroids

Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7

 

What is Dostinex?

 

Cabergoline is a white powder soluble in ethyl alcohol, chloroform, and N, N-dimethylformamide (DMF); slightly soluble in 0.1N hydrochloric acid; very slightly soluble in n-hexane; and insoluble in water.

 

Dostinex Tablets contain cabergoline, a dopamine receptor agonist. The chemical name for cabergoline is 1-[(6-allylergolin-8β-yl)-carbonyl]-1-[3-(dimethylamino) propyl]-3-ethylurea. Its empirical formula is C26H37N5O2, and its molecular weight is 451.62.
Cabergoline is a white powder soluble in ethyl alcohol, chloroform, and N, N-dimethylformamide (DMF); slightly soluble in 0.1N hydrochloric acid; very slightly soluble in n-hexane; and insoluble in water.

Dostinex Tablets, for oral administration, contain 0.5 mg of cabergoline. Inactive ingredients consist of leucine, USP, and lactose, NF.

 

whatsapp:+8613429837396

 

Mechanism of Action


The secretion of prolactin by the anterior pituitary is mainly under hypothalamic inhibitory control, likely exerted through release of dopamine by tuberoinfundibular neurons. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, α1- and α2-adrenergic, and 5-HT1- and 5-HT2-serotonin receptors.

Clinical Studies


The prolactin-lowering efficacy of Dostinex was demonstrated in hyperprolactinemic women in two randomized, double-blind, comparative studies, one with placebo and the other with bromocriptine. In the placebo-controlled study (placebo n=20; cabergoline n=168), Dostinex produced a dose-related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125, 0.5, 0.75, and 1.0 mg twice weekly respectively.

 

In the 8-week, double-blind period of the comparative trial with bromocriptine (cabergoline n=223; bromocriptine n=236 in the intent-to-treat analysis), prolactin was normalized in 77% of the patients treated with Dostinex at 0.5 mg twice weekly compared with 59% of those treated with bromocriptine at 2.5 mg twice daily. Restoration of menses occurred in 77% of the women treated with Dostinex, compared with 70% of those treated with bromocriptine. Among patients with galactorrhea, this symptom disappeared in 73% of those treated with Dostinex compared with 56% of those treated with bromocriptine.

 

Distribution

 

In animals, based on total radioactivity, cabergoline (and/or its metabolites) has shown extensive tissue distribution. Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours. This finding is consistent with the long-lasting prolactin-lowering effect of the drug. Whole body autoradiography studies in pregnant rats showed no fetal uptake but high levels in the uterine wall. Significant radioactivity (parent plus metabolites) detected in the milk of lactating rats suggests a potential for exposure to nursing infants. The drug is extensively distributed throughout the body. Cabergoline is moderately bound (40% to 42%) to human plasma proteins in a concentration-independent manner. Concomitant dosing of highly protein-bound drugs is unlikely to affect its disposition.

Metabolism


In both animals and humans, cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond or the urea moiety. Cytochrome P-450 mediated metabolism appears to be minimal. Cabergoline does not cause enzyme induction and/or inhibition in the rat. Hydrolysis of the acylurea or urea moiety abolishes the prolactin-lowering effect of cabergoline, and major metabolites identified thus far do not contribute to the therapeutic effect.

 

Pharmacodynamics


Dose response with inhibition of plasma prolactin, onset of maximal effect, and duration of effect has been documented following single cabergoline doses to healthy volunteers (0.05 to 1.5 mg) and hyperprolactinemic patients (0.3 to 1 mg). In volunteers, prolactin inhibition was evident at doses >0.2 mg, while doses ≥0.5 mg caused maximal suppression in most subjects. Higher doses produce prolactin suppression in a greater proportion of subjects and with an earlier onset and longer duration of action. In 12 healthy volunteers, 0.5, 1, and 1.5 mg doses resulted in complete prolactin inhibition, with a maximum effect within 3 hours in 92% to 100% of subjects after the 1 and 1.5 mg doses compared with 50% of subjects after the 0.5 mg dose.

 

In hyperprolactinemic patients (N=51), the maximal prolactin decrease after a 0.6 mg single dose of cabergoline was comparable to 2.5 mg bromocriptine; however, the duration of effect was markedly longer (14 days vs. 24 hours). The time to maximal effect was shorter for bromocriptine than cabergoline (6 hours vs. 48 hours).

 

In 72 healthy volunteers, single or multiple doses (up to 2 mg) of cabergoline resulted in selective inhibition of prolactin with no apparent effect on other anterior pituitary hormones (GH, FSH, LH, ACTH, and TSH) or cortisol.

 

Other Related Products:

 

Week Testosterone Enanthate or Test E Anastrozol
1 500mg/week 0.25mg/every other day
2 500mg/wk 0.25mg/eod
3 500mg/wk 0.25mg/eod
4 500mg/wk 0.25mg/eod
5 500mg/wk 0.25mg/eod
6 500mg/wk 0.25mg/eod
7 500mg/wk 0.25mg/eod
8 500mg/wk 0.25mg/eod
9 500mg/wk 0.25mg/eod
10 500mg/wk 0.25mg/eod
11 500mg/wk 0.25mg/eod
12 500mg/wk 0.25mg/eod

 

Dostinex Cabergoline 0.5mg*25pcs Oral Anabolic Steroids CAS 81409-90-7 0

Contact Details
Wuhan Body Biological Co.,Ltd

Contact Person: Penny

Tel: +8613429837396

Send your inquiry directly to us (0 / 3000)

Other Products